Исследование температурного поля пневматического молотка

Представлены результаты экспериментального исследования изменения температуры поверхности рубильного пневматического молотка М-6 по времени при рубке в различных режимах стальной полосы и плиты, чугунной плиты

Metal enrichment processes

There are many processes that can transport gas from the galaxies to their environment and enrich the environment in this way with metals. These metal enrichment processes have a large influence on the evolution of both the galaxies and their environment. Various processes can contribute to the gas transfer: ram-pressure stripping, galactic winds, AGN outflows, galaxy-galaxy interactions and others. We review their observational evidence, corresponding simulations, their efficiencies, and their time scales as far as they are known to date. It seems that all processes can contribute to the enrichment. There is not a single process that always dominates the enrichment, because the efficiencies of the processes vary strongly with galaxy and environmental properties.Comment: 18 pages, 8 figures, accepted for publication in Space Science Reviews, special issue "Clusters of galaxies: beyond the thermal view", Editor J.S. Kaastra, Chapter 17; work done by an international team at the International Space Science Institute (ISSI), Bern, organised by J.S. Kaastra, A.M. Bykov, S. Schindler & J.A.M. Bleeke

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

BACKGROUND: Old age and FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations in patients with acute myeloid leukaemia are associated with early relapse and poor survival. Quizartinib is an oral, highly potent, and selective next-generation FLT3 inhibitor with clinical antileukaemic activity in relapsed or refractory acute myeloid leukaemia. We aimed to assess the efficacy and safety of single-agent quizartinib in patients with relapsed or refractory acute myeloid leukaemia. METHODS: We did an open-label, multicentre, single-arm, phase 2 trial at 76 hospitals and cancer centres in the USA, Europe, and Canada. We enrolled patients with morphologically documented primary acute myeloid leukaemia or acute myeloid leukaemia secondary to myelodysplastic syndromes and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 into two predefined, independent cohorts: patients who were aged 60 years or older with relapsed or refractory acute myeloid leukaemia within 1 year after first-line therapy (cohort 1), and those who were 18 years or older with relapsed or refractory disease following salvage chemotherapy or haemopoietic stem cell transplantation (cohort 2). Patients with an FLT3-ITD allelic frequency of more than 10% were considered as FLT3-ITD positive, whereas all other patients were considered as FLT3-ITD negative. Patients received quizartinib once daily as an oral solution; the initial 17 patients received 200 mg per day but the QTcF interval was prolonged for more than 60 ms above baseline in some of these patients. Subsequently, doses were amended for all patients to 135 mg per day for men and 90 mg per day for women. The co-primary endpoints were the proportion of patients who achieved a composite complete remission (defined as complete remission + complete remission with incomplete platelet recovery + complete remission with incomplete haematological recovery) and the proportion of patients who achieved a complete remission. Efficacy and safety analyses included all patients who received at least one dose of quizartinib (ie, the intention-to-treat population). Patients with a locally assessed post-treatment bone marrow aspirate or biopsy were included in efficacy analyses by response; all other patients were considered to have an unknown response. This study is registered with ClinicalTrials.gov, number NCT00989261, and with the European Clinical Trials Database, EudraCT 2009-013093-41, and is completed. FINDINGS: Between Nov 19, 2009, and Oct 31, 2011, a total of 333 patients were enrolled (157 in cohort 1 and 176 in cohort 2). In cohort 1, 63 (56%) of 112 FLT3-ITD-positive patients and 16 (36%) of 44 FLT3-ITD-negative patients achieved composite complete remission, with three (3%) FLT3-ITD-positive patients and two (5%) FLT3-ITD-negative patients achieving complete remission. In cohort 2, 62 (46%) of 136 FLT3-ITD-positive patients achieved composite complete remission with five (4%) achieving complete remission, whereas 12 (30%) of 40 FLT3-ITD-negative patients achieved composite complete remission with one (3%) achieving complete remission. Across both cohorts (ie, the intention-to-treat population of 333 patients), grade 3 or worse treatment-related treatment-emergent adverse events in 5% or more of patients were febrile neutropenia (76 [23%] of 333), anaemia (75 [23%]), thrombocytopenia (39 [12%]), QT interval corrected using Fridericia\u27s formula (QTcF) prolongation (33 [10%]), neutropenia (31 [9%]), leucopenia (22 [7%]), decreased platelet count (20 [6%]), and pneumonia (17 [5%]). Serious adverse events occurring in 5% or more of patients were febrile neutropenia (126 [38%] of 333; 76 treatment related), acute myeloid leukaemia progression (73 [22%]), pneumonia (40 [12%]; 14 treatment related), QTcF prolongation (33 [10%]; 32 treatment related), sepsis (25 [8%]; eight treatment related), and pyrexia (18 [5%]; nine treatment related). Notable serious adverse events occurring in less than 5% of patients were torsades de pointes (one [<1%]) and hepatic failure (two [1%]). In total, 125 (38%) of 333 patients died within the study treatment period, including the 30-day follow-up. 18 (5%) patients died because of an adverse event considered by the investigator to be treatment related (ten [6%] of 157 patients in cohort 1 and eight [5%] of 176 in cohort 2. INTERPRETATION: Single-agent quizartinib was shown to be highly active and generally well tolerated in patients with relapsed or refractory acute myeloid leukaemia, particularly those with FLT3-ITD mutations. These findings confirm that targeting the FLT3-ITD driver mutation with a highly potent and selective FLT3 inhibitor is a promising clinical strategy to help improve clinical outcomes in patients with very few options. Phase 3 studies (NCT02039726; NCT02668653) will examine quizartinib at lower starting doses. FUNDING: Ambit Biosciences/Daiichi Sankyo

Relevance of the diploma section "Civil protection"

На сьогоднішньому етапі реформування вищої освіти навчальна дисципліна «Цивільний захист» вже не є нормативною і виключена з навчальних планів у вищих навчальних закладах, у тому числі технічного профілю. Але соціально-економічна ситуація в країні, нажаль, ускладнюється. Тому зростає необхідність і важливість питань захисту населення в умовах надзвичайних ситуацій.The discipline "Civil Protection" is not normative any more and excluded from the curriculum in higher educational institutions, including the technical profile at the present stage of reforming higher education. However, unfortunately, the socio-economic situation in the country is becoming more complicated. In these conditions, the need and importance of protecting the population in emergency situations is increasing

Mouthpiece use during heavy resistance exercise affects serum cortisol and lactate

Recent reports suggest the use of mouthpieces may be beneficial at improving aerobic and anaerobic exercise performance. However, the mechanisms of these reported improvements have yet to be elucidated. The purpose of this study was to explore the possible mechanisms of improved performance using the ArmourBite® mouthpiece. Using a within subject randomized treatment design, 15 experienced resistance trained males (19–26 years of age) performed 6 sets of 10 repetitions of free weight back squats at 80% of 1RM with and without a mouthpiece. Blood samples were collected before exercise, after 3 sets (Mid), immediately post (Post), 30 min post (Post-30), 60 min post (Post-60) and 120 min post (Post-120) exercise. Samples were analyzed for lactate and ELISA was used to determine cortisol. Mouthpiece use resulted in more repetitions completed without assistance (54.36 ± 0.61 vs. 53.27 ± 0.79, p = 0.046) and fewer assisted repetitions (6.73 ± 0.79 vs. 5.64 ± 0.61 repetitions, p = 0.046) compared to the control group. Lactate concentrations were lower in the treatment vs. control group at the Post (11.54 ± 2.23 vs. 13.07 ± 2.96 mmol/L, p = 0.023) Post- 30 (4.45 ± 1.94 vs. 5.41 ± 1.90 mmol/L, p = 0.021), and Post-60 (2.07 ± 0.94 vs. 2.55 ± 0.96 mmol/L, p = 0.048) sampling periods. Mouthpiece use lowered cortisol levels at Mid and Post-30 (19.39 ± 6.90 vs. 27.84 ± 14.56 μg/dL, p = 0.02 (22.91 ± 8.47 vs. 31.81 ± 10.79 μg/dL, p = 0.04). Cortisol AUC values showed significant differences within the AUC Pre-Post control and treatment (55.16 ± 23.84 vs. 41.95 ± 2.65 μg/dL, p = 0.02) groups. These data suggest that mouthpiece use may increase performance and decrease stress when used during intense resistance exercise